Volume 10, Number 5—May 2004
Research
Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
Jann-Tay Wang*, Wang-Huei Sheng*, Chi-Tai Fang*, Yee-Chun Chen*, Jiun-Ling Wang*, Chong-Jen Yu*, Shan-Chwen Chang*
, and Pan-Chyr Yang*
, and Pan-Chyr Yang*
Table 2
Initial laboratory data of 76 patients with SARSa
| Laboratory parameters (normal range) | Mean ± standard deviation | No. (%) of patients with abnormal data |
|---|---|---|
| Leukocyte counts (4–9 x 109/L) |
6.0 ± 2.9 |
|
| Leukopenia |
15 (19.7) |
|
| Lymphopeniab |
49 (64.5) |
|
| Platelet counts (150–450 X 109/L) |
159.7±54.0 |
|
| Thrombocytopenia |
35 (46.1) |
|
| AST (<35 U/L) |
36.7±20.0 |
24c (35.3) |
| ALT (<35 U/L) |
27.5±20.4 |
11d (23.9) |
| LDH (<460 U/L) |
597.8±426.0 |
9e (56.3) |
| CK (<190 U/L) |
216.5±444.3 |
17f (26.1) |
| CRP (<0.8 mg/dL) | 3.9±3.6 | 53g (77.9) |
aSARS, severe acute respiratory syndrome; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein.
bDefined as <1 X 109/L.
cOnly 68 patients had been tested.
dOnly 46 patients had been tested.
eOnly 16 patients had been tested.
fOnly 65 patients had been tested.
gOnly 68 patients had been tested.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.